SUVEN LIFE SCIENCES LIMITED The granted claims of the patents are from the mechanism of action include the class of selective H3 Inverseagonist compounds and 5HT6 compounds and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Major Depressive disorder (MDD), Parkinson and Schizophrenia.
With these new patents, Suven has a total of twenty (20) granted patents from Eurasia and six (6) granted patents from Norway. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally" says Venkat Jasti, CEO of Suven.
"Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets. Suven has 3 clinical stage compounds, a Phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the Company has ten (10) internally-discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression, Huntington's disease, Parkinson's disease and pain.
For more information please visit our Web site at http://www.suven.com
Risk Statement:
Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.
CIN: L24110TG1989PLC009713
6/F, Serene Chambers, Rd#7, Banjara Hills Hyderabad 500034, India Tel: 9140 2354 1142 Fax: 9140 2354 1152 Email: info@suven.com
Suven Life Sciences Limited published this content on 03 January 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 03 January 2017 04:47:05 UTC.
Original documenthttp://www.suven.com/PressRelease03Jan17.pdf
Public permalinkhttp://www.publicnow.com/view/E080396AE1C6141A88D01826A1AE494DA0C4FFE7
